Royalty Pharma PLC $RPRX Stock Position Increased by World Investment Advisors

World Investment Advisors increased its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 21.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 58,434 shares of the biopharmaceutical company’s stock after acquiring an additional 10,178 shares during the quarter. World Investment Advisors’ holdings in Royalty Pharma were worth $2,258,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of RPRX. Strs Ohio grew its holdings in shares of Royalty Pharma by 2.8% during the fourth quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 252 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Royalty Pharma by 0.6% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company’s stock valued at $1,673,000 after buying an additional 255 shares in the last quarter. Private Trust Co. NA grew its holdings in shares of Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of Royalty Pharma by 1.0% during the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 289 shares in the last quarter. Finally, Truist Financial Corp grew its holdings in shares of Royalty Pharma by 1.1% during the fourth quarter. Truist Financial Corp now owns 27,769 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 303 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $52.85 on Friday. Royalty Pharma PLC has a twelve month low of $32.15 and a twelve month high of $53.47. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The stock has a market capitalization of $30.43 billion, a PE ratio of 35.95, a P/E/G ratio of 1.47 and a beta of 0.40. The stock has a 50-day simple moving average of $48.31 and a 200 day simple moving average of $43.35.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.22 by $0.08. The firm had revenue of $631.00 million during the quarter, compared to analysts’ expectations of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Research analysts anticipate that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. Royalty Pharma’s dividend payout ratio is currently 63.95%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on RPRX. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. JPMorgan Chase & Co. boosted their target price on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Citigroup boosted their target price on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. UBS Group boosted their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Finally, Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $53.71.

Insider Activity

In other news, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total value of $1,731,895.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of Royalty Pharma stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares of the company’s stock, valued at $10,165,559. This trade represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 155,893 shares of company stock valued at $7,512,360. Company insiders own 18.84% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.